Hemostemix (CVE:HEM) Trading 31% Higher – Time to Buy?

Hemostemix Inc. (CVE:HEMGet Free Report)’s stock price traded up 31% on Thursday . The stock traded as high as C$0.24 and last traded at C$0.19. 727,200 shares changed hands during trading, an increase of 59% from the average session volume of 456,000 shares. The stock had previously closed at C$0.15.

Hemostemix Stock Performance

The firm has a fifty day moving average of C$0.09 and a 200-day moving average of C$0.07. The stock has a market capitalization of C$16.55 million, a price-to-earnings ratio of -9.50 and a beta of 0.20.

About Hemostemix

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.

Read More

Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.